Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
목요일, 8월 20

Abeona Therapeutics Inc

ABEONASDAQ
Trade with Public
Trade with Public
$5.96
-0.17-2.77%
가까이에: Aug 20, 5:00 PM EST
$5.98
0.020.34%
시간외: 4:56 PM EST
실적: Q2 2026 실적이 목 8월 13th에 개장 전 발표되었습니다.
컨퍼런스 콜: 가장 최근의 컨퍼런스 콜은 7일 전 8:30 AM에 시작되었습니다.
웹캐스트를 보려면 클릭하세요.
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Abeona Therapeutics Financials

Abeona Therapeutics (ABEO) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Abeona Therapeutics Q2 EPS $(0.35) Misses $(0.23) Estimate, Sales $11.380M Miss $12.239M Estimate

Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.23) by 52.17 percent. This is a 5.41 percent increase over losses of $(0.37) per share
Benzinga Newsdesk

PRO
Abeona Therapeutics Q1 EPS $(0.30) Beats $(0.35) Estimate, Sales $8.720M Beat $4.572M Estimate

Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.35) by 14.29 percent. This is a 25 percent decrease over losses of $(0.24) per share from
Benzinga Newsdesk

Earnings Scheduled For May 13, 2026

Benzinga Insights

PRO
Abeona Therapeutics Q4 EPS $(0.34) Beats $(0.36) Estimate, Sales $5.420M Beat $5.270M Estimate

Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.36) by 4.49 percent. This is a 142.86 percent decrease over losses of $(0.14) per share
Benzinga Newsdesk

Earnings Scheduled For March 17, 2026

Benzinga Insights

PRO
Abeona Therapeutics Q3 EPS $(0.10) Beats $(0.29) Estimate

Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.29) by 65.52 percent. This is a 84.13 percent increase over losses of $(0.63) per share
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved